Aptargroup (ATR) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Second poster of the month for the kt-5000AI program, following the 31st Society for Neuro-Oncology Annual Meeting Second poster of the month for the kt-5000AI program, following the 31st Society for Neuro-Oncology Annua…

-- First patient dosed with ATR 1072 in the Corventis™ Phase 1/2 clinical trial in PRKAG2 syndrome -- -- Nonclinical data showed ATR 1072 reversed cardiac glycogen accumulation and improved features of PRKAG2 syndrome --…

NEW YORK, Nov. 10, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating AptarGroup, Inc. (NYSE: ATR) on behalf of the company's shareholders. The investigation seeks to determine whether AptarG…

Poster to highlight AI-designed kt-5000AI compounds developed for PTEN-deficient brain tumours Poster to highlight AI-designed kt-5000AI compounds developed for PTEN-deficient brain tumours…

Examine AptarGroup's (ATR) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.…

-- ATR 1072 impacted key characteristics of PRKAG2 syndrome, including accumulation ofcardiac glycogen and cardiac hypertrophy -- -- Data further reinforce scientific rationale for ATR 1072 targeting the root cause ofPRK…

AptarGroup, Inc. ( ATR ) Q3 2026 Earnings Call October 30, 2026 9:00 AM EDT Company Participants Marry Skafidas - Senior Vice President of Investor Relations & Communications Gael Touya - CEO, President & Director Vaness…

AptarGroup NYSE: ATR reported third-quarter 2026 sales growth across its three business segments, while adjusted profitability declined from the prior year as emergency medicine destocking and lower margins in Beauty and…

AptarGroup (ATR) came out with quarterly earnings of $1.52 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.62 per share a year ago.…

EMphora™ platform integrates clinical evidence and predictive modelling to help identify promising cancer patient populations and guide the next phase of research EMphora™ platform integrates clinical evidence and predic…

State of Alaska Department of Revenue raised its holdings in AptarGroup, Inc. (NYSE: ATR) by 53.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm o…

Shares of AptarGroup, Inc. (NYSE: ATR - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten ratings firms that are currently covering the firm, MarketBeat.com reports. Four research analysts …

AptarGroup (ATR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a tre…

Although weak demand and tariffs cloud the Zacks Containers - Paper and Packaging industry's near-term outlook, AVY, ATR and KRT are navigating the challenges well.…

Tidal Investments LLC lowered its position in AptarGroup, Inc. (NYSE: ATR) by 24.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 17,987 s…

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in AptarGroup, Inc. (NYSE: ATR) in a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,200 shar…

AptarGroup, Inc. (ATR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript…

Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleeding Significant reductions in 24-hour chest tube drainage and red blood cell transfusions were also seen,…
No recent releases where the company itself is speaking.
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 11. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

